Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. The viruses that cause these infections continue to live in the body even between outbreaks. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections. Oceanside is the third-largest city in San Diego County, California. Together with Carlsbad and Vista, it forms a tri-city area. The city is located just south of Camp Pendleton, the busiest military base in the United States. Oceanside has experienced dramatic growth since 1970, when its population was 45,000. Much of the city's area was developed into single-family home tracts during the 1970s and 1980s. Since the 1990s, increased commercial and industrial development have diversified Oceanside's economic base. Although the area was first settled by Native Americans, the first European explorers arrived in 1769. The Spanish missionaries under Father Junipero Serra founded Mission San Luis Rey de Francia on a former site of a Luiseño Indian village on the banks of the San Luis Rey River.
The antiviral agents acyclovir (Zovirax), valacyclovir (Valtrex), and famciclovir (Famvir) are commonly used to treat initial and recurrent cases of herpes simplex virus infection, and to lessen the severity of herpes zoster virus infection. Food and Drug Administration considers acyclovir, valacyclovir, and famciclovir category B drugs in pregnancy, but there are few data on early pregnancy exposure. More than 1 percent of susceptible women acquire herpes simplex virus infection during the first trimester of pregnancy, and there is a high prevalence of recurrent infection; therefore, antiviral medication is recommended in a significant number of pregnant women. Pasternak and Hviid investigated the risk of major birth defects in the infants of mothers who took antiviral medication in their first trimester. This retrospective cohort study compiled data from three national registries in Denmark. A cohort of all live births between January 1996 and September 2008 was selected. The authors extracted data on the cohort mothers for prescriptions of oral acyclovir, valacyclovir, and famciclovir, as well as topical acyclovir and penciclovir (Denavir) that were filled from four weeks before conception through birth. The registry was not able to capture data from inpatient prescribing or for over-the-counter formulations of topical acyclovir and penciclovir. Birth defects were identified through the National Patient Register, which lists all diagnoses assigned to persons during hospital admissions and emergency department and outpatient visits. Benefit should outweigh risk AU TGA pregnancy category: B3US FDA pregnancy category: BComments: -Acyclovir (aciclovir) has been safely used to treat genital herpes in women in all stages of pregnancy; data on prenatal exposure to this prodrug is limited, however, animal data suggests low risk. -Women who acquire genital herpes simplex virus (HSV) during late pregnancy should be managed in consultation with maternal-fetal medicine and infectious-disease specialists. -Suppressive therapy late in pregnancy has been shown to reduce the frequency of cesarean delivery among women with recurrent genital herpes by diminishing the frequency of recurrences at term; such treatment may not protect against transmission to neonates in all cases. -Recommended regimen for HSV suppressive therapy in pregnant women with recurrent genital herpes: 500 mg orally 2 times a day starting at 36 weeks gestation. Animal studies have failed to reveal evidence of teratogenicity for either valacyclovir (valaciclovir) or acyclovir (aciclovir; the active metabolite). No significant neonatal toxicity or fetal drug accumulation was noted in a small pharmacokinetic study (n=20) of this drug (500 mg twice daily) administered beginning at 36 weeks' gestation. Pregnancy registry data reported 1 document exposures to this drug or any formulation of its active metabolite, respectively, of which 29 and 756 exposures occurred in the first trimester. Exposure did not indicate an increased incidence of major birth defects compared with the general population in a prospective pregnancy registry; however, there is insufficient data for definitive conclusions regarding exposure during pregnancy.
Find patient medical information for Acyclovir Oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. All about Valacyclovir and pregnancy/breastfeeding. Is it safe to use while pregnant and/or breastfeeding?